Bronchogen
Also known as: Ala-Glu-Asp-Leu, AEDL
Key Facts: Bronchogen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
Bronchogen regulates gene expression in bronchial epithelial cells and lung tissue. Like other Khavinson bioregulators, it works through tissue-specific peptide signaling to normalize cellular function and promote tissue repair in the respiratory system. It may help restore bronchial mucosa and support pulmonary function.
Research Summary
Research from the St. Petersburg Institute of Bioregulation and Gerontology shows Bronchogen's effects on bronchial tissue normalization. Studies in elderly patients demonstrated improvements in respiratory function parameters. Part of the Khavinson peptide bioregulator series with documented effects on tissue-specific gene regulation.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Respiratory/bronchial bioregulator from Khavinson research. Often used for COPD, bronchitis, asthma support, and general lung health. Run in cycles of 10-30 days. Can be combined with other bioregulators.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
Research This Peptide Further
Frequently Asked Questions
What does Bronchogen do?
A tetrapeptide bioregulator (Ala-Glu-Asp-Leu) targeting bronchial and respiratory tissue. Part of the Khavinson bioregulator family. Used for respiratory health support, bronchial conditions, and lung tissue regeneration.
How does Bronchogen work?
Bronchogen regulates gene expression in bronchial epithelial cells and lung tissue. Like other Khavinson bioregulators, it works through tissue-specific peptide signaling to normalize cellular function and promote tissue repair in the respiratory system. It may help restore bronchial mucosa and support pulmonary function.
Is Bronchogen FDA approved?
No, Bronchogen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Bronchogen?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Bronchogen?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Bronchogen or used in similar applications.
Chonluten
PreclinicalA tripeptide bioregulator targeting respiratory and lung tissue. Supports healthy lung function and stomach lining. Regulates inflammatory and proliferative processes in respiratory epithelium.
BioregulatorsTestagen
PreclinicalA peptide bioregulator targeting testicular tissue. Supports healthy testicular function through tissue-specific gene regulation. Part of the Khavinson peptide bioregulator family.
BioregulatorsLivagen
PreclinicalA tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure and gene expression. Research shows it can decondense heterochromatin and activate ribosomal genes, potentially restoring more youthful gene expression patterns in aging cells.
BioregulatorsOvagen
PreclinicalA tripeptide bioregulator (Glu-Asp-Leu) targeting liver and gastrointestinal tissue. Derived from liver tissue extracts, Ovagen modulates gene expression related to detoxification, antioxidant defense, and hepatocellular repair.
BioregulatorsCortagen
PreclinicalA tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support. Regulates neurotrophic signaling and synaptic stability.
BioregulatorsVesugen
PreclinicalA tripeptide bioregulator (Lys-Glu-Asp) targeting vascular tissue. Promotes restoration of blood vessel tissues and normalization of vascular function. Stimulates endothelial cell proliferation markers.
BioregulatorsWant updates on Bronchogen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.